{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T18:21:13Z","timestamp":1789150873218,"version":"build-2803163510"},"reference-count":46,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,12,21]],"date-time":"2024-12-21T00:00:00Z","timestamp":1734739200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,12,21]],"date-time":"2024-12-21T00:00:00Z","timestamp":1734739200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"name":"This study was funded by Genmab A\/S and AbbVie."}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Pharmacokinet"],"published-print":{"date-parts":[[2025,1]]},"DOI":"10.1007\/s40262-024-01464-2","type":"journal-article","created":{"date-parts":[[2024,12,21]],"date-time":"2024-12-21T08:37:34Z","timestamp":1734770254000},"page":"127-141","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Population Pharmacokinetics of Epcoritamab Following Subcutaneous Administration in Relapsed or Refractory B Cell Non-Hodgkin Lymphoma"],"prefix":"10.1007","volume":"64","author":[{"given":"Tommy","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leonid","family":"Gibiansky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Apurvasena","family":"Parikh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcel","family":"van der Linden","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kinjal","family":"Sanghavi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew","family":"Putnins","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariana","family":"Sacchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huaibao","family":"Feng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tahamtan","family":"Ahmadi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manish","family":"Gupta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6997-5533","authenticated-orcid":false,"given":"Steven","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,12,21]]},"reference":[{"key":"1464_CR1","doi-asserted-by":"publisher","first-page":"1800","DOI":"10.1182\/blood-2017-03-769620","volume":"130","author":"M Crump","year":"2017","unstructured":"Crump M, Neelapu SS, Farooq U, Van Den Neste E, Kuruvilla J, Westin J, et al. Outcomes in refractory diffuse large B-cell lymphoma: results from the international SCHOLAR-1 study. Blood. 2017;130:1800\u20138.","journal-title":"Blood"},{"issue":"S1","key":"1464_CR2","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1002\/hon.3154","volume":"41","author":"M Hutchings","year":"2023","unstructured":"Hutchings M. The evolving therapy of DLBCL: bispecific antibodies. Hematol Oncol. 2023;41(S1):107\u201311.","journal-title":"Hematol Oncol"},{"key":"1464_CR3","doi-asserted-by":"publisher","DOI":"10.1002\/hon.3202","author":"A Barraclough","year":"2023","unstructured":"Barraclough A, Hawkes E, Sehn LH, Smith SM. Diffuse large B-cell lymphoma. Hematol Oncol. 2024;42:e3202.","journal-title":"Hematol Oncol"},{"key":"1464_CR4","doi-asserted-by":"publisher","first-page":"2305","DOI":"10.1016\/j.bbmt.2019.08.015","volume":"25","author":"T Jain","year":"2019","unstructured":"Jain T, Bar M, Kansagra AJ, Chong EA, Hashmi SK, Neelapu SS, et al. Use of chimeric antigen receptor T cell therapy in clinical practice for relapsed\/refractory aggressive B cell non-Hodgkin lymphoma: an expert panel opinion from the American Society for Transplantation and Cellular Therapy. Biol Blood Marrow Transplant. 2019;25:2305\u201321.","journal-title":"Biol Blood Marrow Transplant"},{"key":"1464_CR5","unstructured":"Epkinly [package insert]. Plainsboro: Genmab US, Inc.; 2024."},{"key":"1464_CR6","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1038\/s41408-021-00430-6","volume":"11","author":"HJ van der Horst","year":"2021","unstructured":"van der Horst HJ, de Jonge AV, Hiemstra IH, Gelderloos AT, Berry DRAI, Hijmering NJ, et al. Epcoritamab induces potent anti-tumor activity against malignant B-cells from patients with DLBCL, FL and MCL, irrespective of prior CD20 monoclonal antibody treatment. Blood Cancer J. 2021;11:38.","journal-title":"Blood Cancer J"},{"key":"1464_CR7","unstructured":"Tepkinly [summary of product characteristics]. Ludwigshafen: AbbVie Deutschland GmbH & Co. KG; 2024."},{"key":"1464_CR8","unstructured":"Epkinly [Japan package insert]. Tokyo: AbbVie GK, Genmab K.K.; 2023."},{"key":"1464_CR9","unstructured":"Epkinly [Canada product monograph]. St-Laurent: AbbVie Corporation; 2023."},{"key":"1464_CR10","unstructured":"Tepkinly [UK summary of product characteristics]. Maidenhead: AbbVie; 2023."},{"key":"1464_CR11","doi-asserted-by":"publisher","first-page":"102625","DOI":"10.1016\/j.ebiom.2019.102625","volume":"52","author":"PJ Engelberts","year":"2020","unstructured":"Engelberts PJ, Hiemstra IH, de Jong B, Schuurhuis DH, Meesters J, Beltran Hernandez I, et al. DuoBody-CD3xCD20 induces potent T-cell-mediated killing of malignant B cells in preclinical models and provides opportunities for subcutaneous dosing. EBioMedicine. 2020;52:102625.","journal-title":"EBioMedicine"},{"key":"1464_CR12","doi-asserted-by":"publisher","first-page":"1157","DOI":"10.1016\/S0140-6736(21)00889-8","volume":"398","author":"M Hutchings","year":"2021","unstructured":"Hutchings M, Mous R, Clausen MR, Johnson P, Linton KM, Chamuleau MED, et al. Dose escalation of subcutaneous epcoritamab in patients with relapsed or refractory B-cell non-Hodgkin lymphoma: an open-label, phase 1\/2 study. Lancet. 2021;398:1157\u201369.","journal-title":"Lancet"},{"key":"1464_CR13","doi-asserted-by":"publisher","first-page":"2238","DOI":"10.1200\/JCO.22.01725","volume":"41","author":"C Thieblemont","year":"2023","unstructured":"Thieblemont C, Phillips T, Ghesquieres H, Cheah CY, Clausen MR, Cunningham D, et al. Epcoritamab, a novel, subcutaneous CD3xCD20 bispecific T-cell-engaging antibody, in relapsed or refractory large B-cell lymphoma: dose expansion in a phase I\/II trial. J Clin Oncol. 2023;41:2238\u201347.","journal-title":"J Clin Oncol"},{"key":"1464_CR14","doi-asserted-by":"publisher","first-page":"4643","DOI":"10.1111\/cas.15996","volume":"114","author":"K Izutsu","year":"2023","unstructured":"Izutsu K, Kumode T, Yuda J, Nagai H, Mishima Y, Suehiro Y, et al. Subcutaneous epcoritamab monotherapy in Japanese adults with relapsed\/refractory diffuse large B-cell lymphoma. Cancer Sci. 2023;114:4643\u201353.","journal-title":"Cancer Sci"},{"key":"1464_CR15","doi-asserted-by":"publisher","first-page":"1108","DOI":"10.1002\/cpt.2729","volume":"112","author":"T Li","year":"2022","unstructured":"Li T, Hiemstra IH, Chiu C, Oliveri RS, Elliott B, DeMarco D, et al. Semimechanistic physiologically-based pharmacokinetic\/pharmacodynamic model informing epcoritamab dose selection for patients with B-cell lymphomas. Clin Pharmacol Ther. 2022;112:1108\u201319.","journal-title":"Clin Pharmacol Ther"},{"key":"1464_CR16","unstructured":"Bioanalytical method validation: guidance for industry. 2018. https:\/\/www.fda.gov\/media\/70858\/download. Accessed 11 Sept 2024."},{"key":"1464_CR17","unstructured":"European Medicines Agency. Guideline on bioanalytical method validation. 2011. http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/Scientific_guideline\/2011\/08\/WC500109686.pdf. Accessed 11 Sept 2024."},{"key":"1464_CR18","unstructured":"European Medicines Agency. ICH guideline M10 on bioanalytical method validation and study sample analysis step 5. 2022. https:\/\/www.ema.europa.eu\/en\/documents\/scientific-guideline\/ich-guideline-m10-bioanalytical-method-validation-step-5_en.pdf. Accessed 11 Sept 2024."},{"key":"1464_CR19","doi-asserted-by":"publisher","first-page":"1143","DOI":"10.1208\/s12248-014-9650-3","volume":"16","author":"RJ Briggs","year":"2014","unstructured":"Briggs RJ, Nicholson R, Vazvaei F, Busch J, Mabuchi M, Mahesh KS, et al. Method transfer, partial validation, and cross validation: recommendations for best practices and harmonization from the global bioanalysis consortium harmonization team. AAPS J. 2014;16:1143\u20138.","journal-title":"AAPS J"},{"key":"1464_CR20","doi-asserted-by":"publisher","first-page":"1885","DOI":"10.1023\/B:PHAM.0000003390.51761.3d","volume":"20","author":"B DeSilva","year":"2003","unstructured":"DeSilva B, Smith W, Weiner R, Kelley M, Smolec J, Lee B, et al. Recommendations for the bioanalytical method validation of ligand-binding assays to support pharmacokinetic assessments of macromolecules. Pharm Res. 2003;20:1885\u2013900.","journal-title":"Pharm Res"},{"key":"1464_CR21","doi-asserted-by":"publisher","first-page":"1249","DOI":"10.1016\/S0731-7085(99)00244-7","volume":"21","author":"JWA Findlay","year":"2000","unstructured":"Findlay JWA, Smith WC, Lee JW, Nordblom GD, Das I, DeSilva BS, et al. Validation of immunoassays for bioanalysis: a pharmaceutical industry perspective. J Pharm Biomed Anal. 2000;21:1249\u201373.","journal-title":"J Pharm Biomed Anal"},{"key":"1464_CR22","unstructured":"European Medicines Agency. Guideline on immunogenicity assessment of therapeutic proteins. 2017. https:\/\/www.ema.europa.eu\/en\/documents\/scientific-guideline\/guideline-immunogenicity-assessment-therapeutic-proteins-revision-1_en.pdf. Accessed 23 Sept 2024."},{"key":"1464_CR23","unstructured":"Immunogenicity testing of therapeutic protein products \u2014 developing and validating assays for anti-drug antibody detection: guidance for industry. 2019. https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/immunogenicity-testing-therapeutic-protein-products-developing-and-validating-assays-anti-drug. Accessed 23 Sept 2024."},{"key":"1464_CR24","unstructured":"NONMEM User's Guide. San Francisco: University of California, San Francisco, NONMEM Project Group; 1992."},{"key":"1464_CR25","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1007\/s10928-008-9102-8","volume":"35","author":"L Gibiansky","year":"2008","unstructured":"Gibiansky L, Gibiansky E, Kakkar T, Ma P. Approximations of the target-mediated drug disposition model and identifiability of model parameters. J Pharmacokinet Pharmacodyn. 2008;35:573\u201391.","journal-title":"J Pharmacokinet Pharmacodyn"},{"key":"1464_CR26","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1023\/A:1014414520282","volume":"28","author":"DE Mager","year":"2001","unstructured":"Mager DE, Jusko WJ. General pharmacokinetic model for drugs exhibiting target-mediated drug disposition. J Pharmacokinet Pharmacodyn. 2001;28:507\u201332.","journal-title":"J Pharmacokinet Pharmacodyn"},{"key":"1464_CR27","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1208\/s12248-011-9255-z","volume":"13","author":"M Bergstrand","year":"2011","unstructured":"Bergstrand M, Hooker AC, Wallin JE, Karlsson MO. Prediction-corrected visual predictive checks for diagnosing nonlinear mixed-effects models. AAPS J. 2011;13:143\u201351.","journal-title":"AAPS J"},{"key":"1464_CR28","doi-asserted-by":"publisher","first-page":"2036","DOI":"10.1007\/s11095-006-9067-5","volume":"23","author":"K Brendel","year":"2006","unstructured":"Brendel K, Comets E, Laffont C, Laveille C, Mentr\u00e9 F. Metrics for external model evaluation with an application to the population pharmacokinetics of gliclazide. Pharm Res. 2006;23:2036\u201349.","journal-title":"Pharm Res"},{"key":"1464_CR29","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1007\/s10928-005-0016-4","volume":"33","author":"F Mentr\u00e9","year":"2006","unstructured":"Mentr\u00e9 F, Escolano S. Prediction discrepancies for the evaluation of nonlinear mixed-effects models. J Pharmacokinet Pharmacodyn. 2006;33:345\u201367.","journal-title":"J Pharmacokinet Pharmacodyn"},{"key":"1464_CR30","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1002\/cpt.3308","volume":"116","author":"K Lim","year":"2024","unstructured":"Lim K, Zhu XS, Zhou D, Ren S, Phipps A. Clinical pharmacology strategies for bispecific antibody development: learnings from FDA-approved bispecific antibodies in oncology. Clin Pharmacol Ther. 2024;116:315\u201327.","journal-title":"Clin Pharmacol Ther"},{"key":"1464_CR31","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1007\/s40262-019-00823-8","volume":"59","author":"JD Clements","year":"2020","unstructured":"Clements JD, Zhu M, Kuchimanchi M, Terminello B, Doshi S. Population pharmacokinetics of blinatumomab in pediatric and adult patients with hematological malignancies. Clin Pharmacokinet. 2020;59:463\u201374.","journal-title":"Clin Pharmacokinet"},{"key":"1464_CR32","unstructured":"NDA\/BLA multi-disciplinary review and evaluation BLA 761228: Kimmtrak (tebentafusp). 2022. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2022\/761228Orig1s000MultidisciplineR.pdf. Accessed 3 Sept 2024."},{"key":"1464_CR33","doi-asserted-by":"publisher","first-page":"667","DOI":"10.1007\/s11523-023-00989-z","volume":"18","author":"X Miao","year":"2023","unstructured":"Miao X, Wu LS, Lin SXW, Xu Y, Chen Y, Iwaki Y, et al. Population pharmacokinetics and exposure\u2013response with teclistamab in patients with relapsed\/refractory multiple myeloma: results from MajesTEC-1. Target Oncol. 2023;18:667\u201384.","journal-title":"Target Oncol"},{"key":"1464_CR34","doi-asserted-by":"publisher","DOI":"10.1111\/cts.13825","volume":"17","author":"B Bender","year":"2024","unstructured":"Bender B, Li CC, Marchand M, Turner DC, Li F, Vadhavkar S, et al. Population pharmacokinetics and CD20 binding dynamics for mosunetuzumab in relapsed\/refractory B-cell non-Hodgkin lymphoma. Clin Transl Sci. 2024;17: e13825.","journal-title":"Clin Transl Sci"},{"issue":"suppl 1","key":"1464_CR35","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1182\/blood-2020-136311","volume":"136","author":"N Djebli","year":"2020","unstructured":"Djebli N, Morcos PN, Jaminion F, Guerini E, Kratochwil NA, Justies N, et al. Population pharmacokinetics and exposure-response analyses for glofitamab in relapsed\/refractory B-cell non-Hodgkin lymphoma (R\/R NHL): confirmation of efficacy and CRS mitigation in patients with step-up dosing [abstract]. Blood. 2020;136(suppl 1):1\u20132.","journal-title":"Blood"},{"key":"1464_CR36","doi-asserted-by":"publisher","first-page":"247","DOI":"10.2165\/11598090-000000000-00000","volume":"51","author":"L Gibiansky","year":"2012","unstructured":"Gibiansky L, Sutjandra L, Doshi S, Zheng J, Sohn W, Peterson MC, et al. Population pharmacokinetic analysis of denosumab in patients with bone metastases from solid tumours. Clin Pharmacokinet. 2012;51:247\u201360.","journal-title":"Clin Pharmacokinet"},{"key":"1464_CR37","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1007\/s10928-010-9163-3","volume":"37","author":"L Gibiansky","year":"2010","unstructured":"Gibiansky L, Gibiansky E. Target-mediated drug disposition model for drugs that bind to more than one target. J Pharmacokinet Pharmacodyn. 2010;37:323\u201346.","journal-title":"J Pharmacokinet Pharmacodyn"},{"key":"1464_CR38","doi-asserted-by":"publisher","first-page":"633","DOI":"10.2165\/11535960-000000000-00000","volume":"49","author":"NL Dirks","year":"2010","unstructured":"Dirks NL, Meibohm B. Population pharmacokinetics of therapeutic monoclonal antibodies. Clin Pharmacokinet. 2010;49:633\u201359.","journal-title":"Clin Pharmacokinet"},{"key":"1464_CR39","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1111\/j.1365-2125.2006.02752.x","volume":"63","author":"B Agoram","year":"2007","unstructured":"Agoram B, Sutjandra L, Sullivan JT. Population pharmacokinetics of darbepoetin alfa in healthy subjects. Br J Clin Pharmacol. 2007;63:41\u201352.","journal-title":"Br J Clin Pharmacol"},{"key":"1464_CR40","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1245\/ASO.2004.01.911","volume":"11","author":"GW Carlson","year":"2004","unstructured":"Carlson GW. Age and the incidence of sentinel lymph node metastases in melanoma. Ann Surg Oncol. 2004;11:236\u20137.","journal-title":"Ann Surg Oncol"},{"key":"1464_CR41","doi-asserted-by":"publisher","first-page":"1085","DOI":"10.1096\/fasebj.10.9.8801171","volume":"10","author":"S Chevalier","year":"1996","unstructured":"Chevalier S, Ferland G, Tuchweber B. Lymphatic absorption of retinol in young, mature, and old rats: influence of dietary restriction. FASEB J. 1996;10:1085\u201390.","journal-title":"FASEB J"},{"key":"1464_CR42","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1023\/A:1015880819328","volume":"7","author":"A Supersaxo","year":"1990","unstructured":"Supersaxo A, Hein WR, Steffen H. Effect of molecular weight on the lymphatic absorption of water-soluble compounds following subcutaneous administration. Pharm Res. 1990;7:167\u20139.","journal-title":"Pharm Res"},{"key":"1464_CR43","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1016\/j.ddtec.2005.05.006","volume":"2","author":"DN McLennan","year":"2005","unstructured":"McLennan DN, Porter CJ, Charman SA. Subcutaneous drug delivery and the role of the lymphatics. Drug Discov Today Technol. 2005;2:89\u201396.","journal-title":"Drug Discov Today Technol"},{"key":"1464_CR44","doi-asserted-by":"publisher","first-page":"2530","DOI":"10.1007\/s11095-011-0481-y","volume":"28","author":"T Kakkar","year":"2011","unstructured":"Kakkar T, Sung C, Gibiansky L, Vu T, Narayanan A, Lin SL, et al. Population PK and IgE pharmacodynamic analysis of a fully human monoclonal antibody against IL4 receptor. Pharm Res. 2011;28:2530\u201342.","journal-title":"Pharm Res"},{"key":"1464_CR45","doi-asserted-by":"publisher","first-page":"e1","DOI":"10.2165\/11599820-000000000-00000","volume":"51","author":"A Chakraborty","year":"2012","unstructured":"Chakraborty A, Tannenbaum S, Rordorf C, Lowe PJ, Floch D, Gram H, et al. Pharmacokinetic and pharmacodynamic properties of canakinumab, a human anti-interleukin-1\u03b2 monoclonal antibody. Clin Pharmacokinet. 2012;51:e1-18.","journal-title":"Clin Pharmacokinet"},{"key":"1464_CR46","doi-asserted-by":"publisher","first-page":"793","DOI":"10.2165\/11594240-000000000-00000","volume":"50","author":"L Sutjandra","year":"2011","unstructured":"Sutjandra L, Rodriguez RD, Doshi S, Ma M, Peterson MC, Jang GR, et al. Population pharmacokinetic meta-analysis of denosumab in healthy subjects and postmenopausal women with osteopenia or osteoporosis. Clin Pharmacokinet. 2011;50:793\u2013807.","journal-title":"Clin Pharmacokinet"}],"container-title":["Clinical Pharmacokinetics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40262-024-01464-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40262-024-01464-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40262-024-01464-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,25]],"date-time":"2025-01-25T09:51:51Z","timestamp":1737798711000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40262-024-01464-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12,21]]},"references-count":46,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,1]]}},"alternative-id":["1464"],"URL":"https:\/\/doi.org\/10.1007\/s40262-024-01464-2","relation":{},"ISSN":["0312-5963","1179-1926"],"issn-type":[{"value":"0312-5963","type":"print"},{"value":"1179-1926","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,12,21]]},"assertion":[{"value":"20 November 2024","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 December 2024","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was funded by Genmab A\/S and AbbVie.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"T.L., M.v.d.L., K.S., M.P., M.S., H.F., T.A., M.G., and S.X. are employees of Genmab. T.A. owns stock in Genmab. L.G. is an employee of QuantPharm LLC and is a paid consultant of Genmab. A.P. is an employee and stockholder of AbbVie.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Deidentified individual participant data will not be available upon request for further analyses by external independent researchers. Aggregated clinical trial data from the trials are provided via publicly accessible study registries\/databases as required by law. For more information, please contact clinicaltrials@genmab.com.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of data and material"}},{"value":"Both EPCORE NHL-1 and EPCORE NHL-3 protocols were approved by an institutional ethics committee before the start of the trials. The trials were conducted in compliance with the International Council for Harmonisation Good Clinical Practice E6(R2) guidelines, local guidelines (Japan Good Clinical Practice for EPCORE NHL-3), principles of the Declaration of Helsinki, and relevant regulatory requirements.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"All patients reviewed and signed informed consent forms before enrollment.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Because of the nature of this study, consent to publish was waived.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Conceptualization: T.L., A.P., M.G., and S.X. Methodology: T.L., L.G., and M.v.d.L. Formal analysis and investigation: T.L., L.G., M.v.d.L, M.S., and H.F. Writing, original draft preparation: T.L. and S.X. Funding acquisition: T.L. and M.G. Resources: K.S. and M.P. Supervision: T.L., M.G., and S.X. All authors participated in the critical review and revision of this manuscript and provided approval of the manuscript for submission.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author contributions"}},{"value":"Not applicable.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}}]}}